RxDoctor Payments Data

Kelly Logli

Nurse Practitioner · Rockford, ILNPI 1730404419

Payments from drug & device makers

$1,077in general payments, 2019–2025

Across 21 payments — averaging $51.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$330
  • Nevro Corp.$182
  • Novo Nordisk$148
  • Lilly USA, LLC$98
  • Xeris Pharmaceuticals, Inc.$95
  • Boehringer Ingelheim$87
  • plus $138 from 5 others

What the payments were for

  • Food & beverage$80274%
  • Other$27526%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,077 in reported general payments places this provider in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$37,302
Medicare patients
201
Services billed
760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide245$440,294
JardianceEmpagliflozin230$320,235
MounjaroTirzepatide136$211,035
TrulicityDulaglutide129$188,912
Fiasp FlextouchInsulin Aspart (Niacinamide)89$166,496
Humulin R U-500 KwikpenInsulin Regular, Human73$161,296
Tresiba Flextouch U-200Insulin Degludec55$67,955
FarxigaDapagliflozin Propanediol63$63,886
Tresiba Flextouch U-100Insulin Degludec71$60,834
JanuviaSitagliptin Phosphate53$47,822
Lyumjev Kwikpen U-100Insulin Lispro-Aabc27$37,356
Novolog FlexpenInsulin Aspart92$36,374
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog52$34,073
Lantus SolostarInsulin Glargine,hum.Rec.Anlog144$32,182
Humulin R U-500Insulin Regular, Human13$24,485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$148$480,775309 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$98$407,729309 claims
Boehringer IngelheimJardiance, Tradjenta$87$337,539241 claims
MerckJanuvia$18$47,82253 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$16$26,08952 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →